Neoleukin Therapeutics Insiders

NLTXDelisted Stock  USD 0.69  0.01  1.43%   
Neoleukin Therapeutics employs about 7 people. The company is managed by 9 executives with a total tenure of roughly 13 years, averaging almost 1.0 years of service per executive, having 0.78 employees per reported executive. Break down of Neoleukin Therapeutics' management performance can provide insight into the company performance.
Kamran Alam  President
CFO, Vice President - Finance
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Neoleukin Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1871) % which means that it has lost $0.1871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3788) %, meaning that it created substantial loss on money invested by shareholders. Neoleukin Therapeutics' management efficiency ratios could be used to measure how well Neoleukin Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Neoleukin Therapeutics Workforce Comparison

Neoleukin Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 776. Neoleukin Therapeutics maintains roughly 7.0 in number of employees contributing less than 1% to equities under Health Care industry.

Neoleukin Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neoleukin Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neoleukin Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Neoleukin Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Neoleukin Therapeutics Notable Stakeholders

A Neoleukin Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Neoleukin Therapeutics often face trade-offs trying to please all of them. Neoleukin Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Neoleukin Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kamran AlamCFO, Vice President - FinanceProfile
Umut UlgeVP DevelProfile
MS MDChief OfficerProfile
Donna JDGen LegalProfile
Carl WalkeySr DevelProfile
Bill ArthurVP ResearchProfile
Sean SmithVP OfficerProfile
David BakerCofounder BoardProfile
Jonathan MDPresident, CEOProfile

About Neoleukin Therapeutics Management Performance

The success or failure of an entity such as Neoleukin Therapeutics often depends on how effective the management is. Neoleukin Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Neoleukin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Neoleukin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neoleukin Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Please note, the imprecision that can be found in Neoleukin Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Neoleukin Therapeutics. Check Neoleukin Therapeutics' Beneish M Score to see the likelihood of Neoleukin Therapeutics' management manipulating its earnings.

Neoleukin Therapeutics Workforce Analysis

Traditionally, organizations such as Neoleukin Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Neoleukin Therapeutics within its industry.

Neoleukin Therapeutics Manpower Efficiency

Return on Neoleukin Therapeutics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee8.2M
Net Loss Per Executive6.4M
Working Capital Per Employee12.6M
Working Capital Per Executive9.8M
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in Neoleukin Stock

If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
Commodity Directory
Find actively traded commodities issued by global exchanges
CEOs Directory
Screen CEOs from public companies around the world
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency